Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Salloway

Showing results (41-50 of 174) with videos related to

Pageof 18
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 31, 2022
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's diseaseOskar Hansson, Rebecca M Edelmayer, Adam L Boxer, et al.
Alzheimer'S Research & Therapy|January 8, 2011
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's diseaseRandall J Bateman, Paul S Aisen, Bart De Strooper, et al.
JAMA Neurology|November 22, 2021
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer DiseaseStephen Salloway, Spyros Chalkias, Frederik Barkhof, et al.
The American Journal of Geriatric Pharmacotherapy|December 13, 2006
Recommendations for best practices in the treatment of Alzheimer's disease in managed careHoward M Fillit, Rachelle Smith Doody, Kimberly Binaso, et al.
Nature Aging|December 19, 2025
Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disordersMarwan N Sabbagh, Jeffrey L Cummings, Clive Ballard, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 15, 2018
Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's diseaseLeslie M Shaw, Jalayne Arias, Kaj Blennow, et al.
Alzheimer'S Research & Therapy|November 29, 2022
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's diseaseRandall J Bateman, Jeffrey Cummings, Scott Schobel, et al.
Neurology|February 13, 2018
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumabEnchi Liu, Dai Wang, Reisa Sperling, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's diseaseEric Siemers, Todd Feaster, Gopalan Sethuraman, et al.
Expert Review of Neurotherapeutics|December 27, 2014
Charting a path toward combination therapy for Alzheimer's diseaseDiane Stephenson, Dan Perry, Cynthia Bens, et al.
Pageof 18

Showing results (41-50 of 174) with videos related to

Sort By:
Pageof 18
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 31, 2022
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's diseaseOskar Hansson, Rebecca M Edelmayer, Adam L Boxer, et al.
Alzheimer'S Research & Therapy|January 8, 2011
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's diseaseRandall J Bateman, Paul S Aisen, Bart De Strooper, et al.
JAMA Neurology|November 22, 2021
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer DiseaseStephen Salloway, Spyros Chalkias, Frederik Barkhof, et al.
The American Journal of Geriatric Pharmacotherapy|December 13, 2006
Recommendations for best practices in the treatment of Alzheimer's disease in managed careHoward M Fillit, Rachelle Smith Doody, Kimberly Binaso, et al.
Nature Aging|December 19, 2025
Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disordersMarwan N Sabbagh, Jeffrey L Cummings, Clive Ballard, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 15, 2018
Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's diseaseLeslie M Shaw, Jalayne Arias, Kaj Blennow, et al.
Alzheimer'S Research & Therapy|November 29, 2022
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's diseaseRandall J Bateman, Jeffrey Cummings, Scott Schobel, et al.
Neurology|February 13, 2018
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumabEnchi Liu, Dai Wang, Reisa Sperling, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's diseaseEric Siemers, Todd Feaster, Gopalan Sethuraman, et al.
Expert Review of Neurotherapeutics|December 27, 2014
Charting a path toward combination therapy for Alzheimer's diseaseDiane Stephenson, Dan Perry, Cynthia Bens, et al.
Pageof 18